top of page

Management Team

Pini Orbach, PhD  Chairman

Dr. Orbach is the Head of the Pharma Division of Arkin Holdings and a member of the board at several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a PhD from the University of Florida, and was a postdoctoral fellow at Harvard Medical School - Massachusetts General Hospital.

​

Roy Golan, CPA, LLM  Executive VP & CFO

Mr. Golan is a registered CPA with a broad experience in aspects of Nasdaq, IPOs and M&As. Prior to joining BioSight, Mr. Golan served in several financial management positions in the biotech industry, including as the CFO of Neuroderm, where he had a pivotal role in their successful Nasdaq IPO, two Follow-On Offerings, and Neuroderm's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of US$1.1 billion. Mr. Golan started his career at PriceWaterhouseCoopers (PWC). Mr. Golan is a registered CPA, holds a B.A. in Accounting and Business from the Israeli College of Management School of Business and an LL.M. in Law from Bar Ilan University. 

​

​

Liat Flaishon, MD, PhD  VP Medical Affairs

Dr. Flaishon brings 20 years of experience in managing clinical trials in the pharmaceutical industry and as a board-certified internal medicine physician. Prior to joining BioSight, Dr. Flaishon served in several positions in the industry, including VP Clinical Affairs at Intec Pharma, a Phase 3 biotech company, where she led early and advanced clinical projects, and a Director of Drug Safety Risk Management Plans in the global Pharmacovigilance Department at Teva Pharmaceuticals, where she accompanied products from early development stages to commercialization. Dr. Flaishon served as an internal medicine physician at the Tel-Aviv Sourasky Medical Center. Dr. Flaishon holds a medical degree from Tel-Aviv University and a PhD degree in Immunology from the Weizmann Institute of Science.

​

Shoshi Tessler, PhD  VP Research & Development

Dr. Tessler brings to BioSight over 20 years of experience in the pharmaceutical industry, leading a broad range of drug development projects and activities, from lead-stage to Phase 3 and registration. Dr. Tessler previously served as the VP R&D of Enzymotec and as a Senior Director Project Champion at the Innovative R&D in Teva Pharmaceuticals, leading diverse drug development projects throughout their life cycle. Her experience and responsibilities included management of all aspects of drug development, including CMC, pharmacology, toxicology, mechanism of action, regulatory affairs, clinical development, and intellectual property. Dr. Tessler received her PhD from the Technion, Haifa, Israel in the area of growth factors and cancer development, followed by a post-doctoral fellowship at the Babraham Institute, Cambridge, UK.

​

Margarita Shumilov, B Pharm, PhD  Director, CMC & QA

​​​Dr. Shumilov brings vast experience in various CMC aspects of drug development & commercialization. Prior to joining Biosight, ​​​Dr. Shumilov served as a Team Leader in the Pharmaceutical Operations group and a CMC Projects Leader at the Innovative R&D division of Teva Pharmaceuticals Industries, where she successfully led the CMC aspects of Teva’s products for FDA approval. ​​​Dr. Shumilov specializes in the development of various sterile and solid dosage forms and drug-device combination products, from early preclinical stages to commercialization. In addition, ​​​Dr. Shumilov has an extensive experience in the scale-up, optimization, and validation of the manufacturing processes. Dr. Shumilov is a licensed pharmacist and holds a PhD in Pharmaceutical Sciences from the Hebrew University of Jerusalem.

​

​

bottom of page